Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Lowered to $41.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its price objective lowered by Piper Sandler from $45.00 to $41.00 in a research note released on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy […]
More Stories
Head to Head Contrast: Bitcoin Depot (NASDAQ:BTM) and NU (NYSE:NU)
NU (NYSE:NU – Get Free Report) and Bitcoin Depot (NASDAQ:BTM – Get Free Report) are both finance companies, but which...
Neoleukin Therapeutics (NASDAQ:NLTX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Survey
Neoleukin Therapeutics (NASDAQ:NLTX – Get Free Report) and Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) are both small-cap medical companies,...
Fiera Capital Co. (TSE:FSZ) Given Average Recommendation of “N/A” by Analysts
Shares of Fiera Capital Co. (TSE:FSZ – Get Free Report) have been given an average recommendation of “N/A” by the...
SMS Alternatives (OTCMKTS:CICN) & TruBridge (NASDAQ:TBRG) Financial Analysis
TruBridge (NASDAQ:TBRG – Get Free Report) and SMS Alternatives (OTCMKTS:CICN – Get Free Report) are both medical companies, but which...
IPG Photonics (NASDAQ:IPGP) versus Photronics (NASDAQ:PLAB) Head-To-Head Survey
IPG Photonics (NASDAQ:IPGP – Get Free Report) and Photronics (NASDAQ:PLAB – Get Free Report) are both computer and technology companies,...
Precision Drilling Co. (TSE:PD) Given Average Recommendation of “Buy” by Brokerages
Shares of Precision Drilling Co. (TSE:PD – Get Free Report) (NYSE:PDS) have been given a consensus rating of “Buy” by...